PIPELINE > TRIAL OVERVIEW
Phase
1
Enrolling
[Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Oligometastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer*
*
This clinical trial is currently being conducted in Canada.
†
[Ac-225]-PSMA-62 is administered intravenously.
For information on trial enrollment, locations, and more, call
1-800-545-5979.
or visit www.clinicaltrials.gov for more information on this trial